Zydus Cadila gets final USFDA nod for Parkinson's treatment drug
Zydus Cadila has received final approval from the US health regulator to market Amantadine tablets, used for the treatment of Parkinson's disease and select viral infections, in the American market.T... Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated June 01, 2016 titled "Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules". Updates on Registrar & Share Transfer Agent
Cadila Healthcare Ltd has submitted to BSE a copy of Notice informing the shareholders regarding the appointment of M/s. Link Intime India Pvt Ltd as its Registrar & Share Transfer Agent with effective from June 01, 2016. Buy Cadila Healthcare with a target of Rs 346: Mitesh Thacker
Buy Cadila Healthcare with a target of Rs 346 and a stop loss of Rs 328 Investors' Presentation
Cadila Healthcare Ltd has submitted to BSE a copy of Investors' Presentation.
Zydus Cadila gets USFDA's final nod for fungal treatment drug
Shares of Cadila Healthcare, the group's listed entity, were trading 0.41 per cent up at Rs 319.45 on BSE in the afternoon session. Zydus receives final approval from the USFDA for Voriconazole Tablets
Cadila Healthcare Ltd has informed BSE regarding a Press Release dated May 25, 2016 titled "Zydus receives final approval from the USFDA for Voriconazole Tablets". Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting
Cadila Healthcare Ltd has submitted to BSE a copy of Press Release dated May 24, 2016 titled 'Two presentations highlighting Zydus drug, Lipaglyn will be featured at the AACE Annual meeting' Underperform on Cadila Healthcare with a target at Rs 346: CLSA
The pricing pressure in the key US product, HCQS has started to show up which will weigh on the stock. HCQS could see further price declines as competitive intensity rises, said the note Cadila: Concerns over US, India growth remain
Cadila's Moraiya plant, which contributed about 60% of its US revenues, is under the USFDA scanner since 2014